HealthDay News — For postmenopausal women, conjugated equine estrogen (CEE) alone is associated with a long-term decrease in breast cancer incidence, while CEE plus medroxyprogesterone acetate (MPA) is associated with increased incidence, according to a study presented at the annual San Antonio Breast Cancer Symposium, held from Dec. 10 to 14 in Texas.

Rowan T. Chlebowski, M.D., Ph.D., from the Harbor-UCLA Medical Center in Torrance, California, and colleagues examined the long-term effect of CEE plus MPA versus placebo for women with a uterus or CEE alone versus placebo for women with prior hysterectomy. Participants were postmenopausal women aged 50 to 79 years.

The researchers found that CEE use alone was associated with a significantly reduced breast cancer incidence during the intervention period (hazard ratio, 0.76), with a greater reduction for women with no prior hormone therapy (HT) use and with a gap time of at least five years. Through 16.1 years of cumulative follow-up, CEE use alone continued to be associated with a significantly reduced incidence of breast cancer (hazard ratio, 0.77), while subgroup differences were no longer significant. CEE plus MPA use was associated with a significantly increased breast cancer incidence (hazard ratio, 1.26) during the intervention period, with a greater increase for women with prior HT use and women with a gap time of less than five years. CEE plus MPA continued to be associated with a significant increase in breast cancer incidence through 18.3 years of cumulative follow-up; subgroup differences were no longer significant.


Continue Reading

“The discordance between the randomized clinical trial findings with respect to estrogen alone use and observational findings are difficult to reconcile,” Chlebowski said in a statement.

One author disclosed financial ties to the pharmaceutical industry.

Press Release

More Information

Related Articles

Follow @EndoAdvisor